Digital health company in the business of developing smartphone apps for respiratory patients, Resapp Health Ltd (ASX: RAP), has gone into voluntary trading suspension today pending the release of an announcement regarding its Smartcough study results.
Speculative investors have had their eye on Resapp Health for some time and the company reported strong results from its clinical study into sleep apnoea back in September, with its smartphone app delivering surprising results.
The Smartcough study will evaluate the efficiency of a Resapp Health app to diagnose and manage respiratory diseases, including childhood acute respiratory disease, with 1,470 patients involved in the study.
Resapp is working hard to cement its credibility as a viable healthcare technology company, with breathing disorders company Somnomed Limited (ASX: SOM) and respected sleep disorders product manufacturer, ResMed Inc (ASX: RMD), also attempting to tap into the sleep treatment market, albeit via slightly different avenues.
